News and events

Novel Approaches to Improve the Effector Function of Monoclonal Antibodies

September 8, 2021

Dr. Shawn Chen, Professor at the Biodesign Center for Immunotherapy, Vaccines and Virotherapy, will be presenting at the Center for Emerging, Zoonotic and Arthropod-borne Pathogens Distinguished Speaker Seminar Series. The seminar will include a 45-minute talk followed by a 15-minute Q&A session. For more information, please visit: https://infectiousdisease.fralinlifesci.vt.edu/Education.html Zoom Link: https://virginiatech.zoom.us/j/89419666443

TNF Superfamily Arming and Leukocyte Based Delivery of Oncolytic Myxoma Virus in a Syngeneic Murine Lung Metastasis Model

August 30, 2021

Presented by John Christie, Biodesign Center for Immunotherapy, Vaccines, and Virotherapy Viroholics is a weekly seminar series hosted by the Biodesign Center for Immunotherapy, Vaccines, and Virotherapy. Join via Zoom from Pc, Mac, Linux, iOS or Android: https://asu.zoom.us/j/88240683626

SARS-CoV-2: a theme and variations

August 11, 2021

The celebrations were well underway. America seemed to be emerging from the depths of the COVID-19 crisis, following some of the darkest days in the nation’s history. A vast reduction in infections, hospitalizations, and fatalities, driven by improved therapies and above all, a suite of highly effective vaccines, had brought a collective sigh of relief. The July 4th festivities were euphorically anticipated, marking not only the nation’s independence from colonial rule but its...

Improving a virus’ cancer-killing potency

June 2, 2021

In recent years, an unusual new domain in cancer research has opened up. The idea is to use infectious pathogens to attack and kill cancerous cells. So-called oncolytic viruses, in particular, have shown great promise for targeting cancer cells, while leaving normal, healthy cells intact. In new research, Rahman Masmudur and his colleagues describe a method for improving the effectiveness of a powerful oncolytic virus known as myxoma virus.   A member of the pox family of viruses,...

Arizona Town Hall Meeting on COVID-19 Vaccine Safety

March 23, 2021

Scientists at Arizona State University and University of Arizona have joined a national effort to educate the general public about COVID-19 vaccination. Leading Arizona's discussions will be:  Felicia Goodrum, PhD, University of Arizona College of Medicine James Alwine, PhD, University of Arizona Grant McFadden, PhD, director, Biodesign Center for Immunotherapy, Vaccines and Virotherapy  Brenda Hogue, PhD, Biodesign Center for Immunotherapy, Vaccines and...

Introduction to the molecular biology of COVID-19 vaccines and vaccine candidates

January 19, 2021

Ian Hogue, PhD Biodesign Center for Immunotherapy, Vaccines and Virotherapy presents: Introduction to the molecular biology of COVID-19 vaccines and vaccine candidates This is part of the Navajo Emerging Infection and Tribal Communities Conference on Emerging Infection and Tribal Communities. Registration is free.  Register

How a persistent infection lifestyle impacts viral genomic diversity and evolution

September 3, 2020

Moriah Louise Szpara, PhD Associate Professor Departments of Biology and Biochemistry & Molecular Biology, Center for Infectious Disease Dynamics (CIDD) Huck Institutes of the Life Sciences Penn State University Title: “How a persistent infection lifestyle impacts viral genomic diversity and evolution” Join via Zoom from PC, Mac, Linux, iOS or Android:   https://asu.zoom.us/j/98635363581?pwd=N1h5SS96aEFTSUx3QzNxSVN6ZXdqQT09    Password:...

An unconventional solution: Researchers recognized by ASU Women and Philanthropy for Salmonella-based cancer therapy

May 13, 2020

Standard-of-care treatments—chemotherapy and radiation—remain at the forefront of cancer therapy, but in light of the high rate of recurrence and treatment failure still observed for most cancer subtypes and the high toxicity conferred by current practices, new and innovative therapies are being pursued.   These approaches include engineering viruses and bacteria to attack cancer cells, while leaving non-cancerous, healthy cells untouched. This line of research is quickly...

ASU scientific team finds new, unique mutation in coronavirus study

May 7, 2020

As the coronavirus pandemic has swept across the U.S., in addition to tracking the number of COVID-19 daily cases, there is a worldwide scientific community engaged in tracking the SARS-CoV-2 virus itself. Efrem Lim leads a team at Arizona State University that looks at how the virus may be spreading, mutating and adapting over time. To trace the trail of the virus worldwide, Lim’s team is using a new technology at ASU’s Genomics Facility called next-generation...

ASU Biodesign Institute spinout, OncoMyx Therapeutics, and Skysong Innovations complete licensing agreement

February 25, 2020

OncoMyx Therapeutics, an Arizona State University (ASU) spinout and privately-held oncolytic immunotherapy company founded on the myxoma virus (MYXV) platform, has finalized a licensing agreement with Skysong Innovations, ASU's technology transfer organization. OncoMyx is developing oncolytic immunotherapies to treat cancer, based on the work of Grant McFadden, director of the Biodesign Institute's Center for Immunotherapy, Vaccines and Virotherapy  and a professor in the...